Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

Shares of Hims & Hers Health Inc. ended Tuesday over 5% higher, lifting retail investor mood after the telehealth company announced it was adding two new weight-loss medications to its platform.

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of branded versions of Eli Lilly’s (NYSE:LLY) popular weight loss therapy ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic ...

In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of branded versions of Eli Lilly’s (NYSE:LLY) popular weight loss therapy ...